GE HealthCare Technologies Inc. (GEHC)

FairStock Score: 59/100 — STEADY

Key Financials

Strengths

• Dominant market positions in medical imaging with high switching costs and recurring revenue streams
• Strong Q4 operational performance with 10.34% net margin and $1.7B free cash flow generation
• Exceptional Piotroski F-Score of 8/9 indicating excellent financial statement quality and operational momentum
• Essential healthcare exposure with secular tailwinds from aging demographics and diagnostic demand
• 22.38% ROE demonstrating profitable capital deployment at the equity level

Concerns

• Severe valuation disconnect: trading 194% above Graham Number with 37.72x EV/EBITDA—unsustainable premium
• Alarmingly low ROCE of 5.47% suggests capital inefficiency despite strong ROE, indicating leverage dependency
• Altman Z-Score of 1.33 in distress zone raises concerns about financial stability under stress scenarios
• Modest FCF yield of 2.7% offers limited margin of safety for downside protection

AI Analysis

I'm examining GE HealthCare with measured skepticism. The company operates in an attractive sector—healthcare diagnostics and imaging—with genuine competitive advantages through brand recognition, regulatory moats, and sticky customer relationships. The Q4 margin of 10.34% and $1.7B in free cash flow demonstrate operational competence. However, I'm troubled by several metrics. The Graham Number sits at $25.71 versus a $75.63 price—a staggering 194% overvaluation that would make Graham run for the exits. The ROCE of 5.47% is deeply concerning; for every dollar of capital employed, the company generates only five cents of return above cost of capital. This suggests either capital inefficiency or a maturing business reinvesting heavily without proportional returns. The EV/EBITDA of 37.72x is extraordinarily expensive for a healthcare equipment manufacturer, even accounting for quality. The Altman Z-Score of 1.33 suggests moderate financial distress risk. While the Piotroski F-Score of 8/9 shows strong recent operational trends and 22.38% ROE appears excellent, the ROCE disconnect is the real concern—ROE can be inflated by leverage, which the 0.99 D/E ratio confirms. At this valuation, I'd require visibility of 12-15% annual free cash flow growth for five years and improving ROCE toward 10%+ to justify holding. Currently, this feels like a quality business at a quality-destroying price.

Bull Case

Healthcare diagnostics are mission-critical infrastructure with durable competitive moats and recurring revenue characteristics. GE HealthCare's diversified portfolio across imaging, patient monitoring, and pharmaceutical diagnostics provides recession-resistant growth exposure, particularly as global healthcare spending accelerates. Recent operational execution and 8/9 Piotroski strength suggest management is executing well.

Bear Case

The valuation is fundamentally disconnected from intrinsic worth at 194% above Graham Number, leaving zero margin of safety. Deteriorating ROCE despite strong margins indicates capital is being consumed unproductively, and any business slowdown with the Altman Z-Score at 1.33 could trigger distress. The market is pricing in perfection with no room for disappointment.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer